Introduction 57
Accumulation of activated lung myofibroblasts and excessive deposition of extracellular 58 matrix (ECM) produced by these cells result in lung tissue contraction, as has been observed 59 in fibrotic lung tissues (Upagupta et al., 2018) . This can disrupt lung function, and therefore, 60 inhibition of fibrotic processes may alter the progression of lung fibrosis-related diseases. 1999b; Gurujeyalakshmi et al., 1999) . However, the precise mechanisms via 84 which pirfenidone suppresses lung fibrosis are still unclear. 85 In this study, we evaluated the effects pirfenidone on TGF-β1-mediated contraction of 86 ECM and migration toward fibronectin of lung fibroblasts isolated from patients with lung 87 fibrosis and compared them with those of normal lung fibroblasts for understanding the 88 mechanisms mediating lung fibroblast-dependent antifibrotic effects of pirfenidone. In 89 addition, we focused on the two molecular targets of pirfenidone, namely, collagen triple helix 90 repeat containing protein 1 (CTHRC1) and four-and-a-half LIM domain protein 2 (FHL2); the 91 levels of these two proteins were previously demonstrated to be attenuated in the 92 bleomycin-induced lung fibrosis model and CTHRC1 secretion was inhibited in the 93 TGF-β1-induced normal primary human lung fibroblasts (Bauer er al.,2015). Our results 94 provided important insights into pirfenidone-mediated antifibrotic processes. Furthermore, we 95 established novel evidence of clinical markers for predicting responses to pirfenidone, which 96 will assist in selecting therapy based on in vitro functional measurements of lung fibrotic 97 fibroblast and clinicopathological information formally evaluated using multidisciplinary 98
diagnosis (MDD). 99
Results 100
Clinical and demographic characteristics 101
The clinical and demographic characteristics of the patients are shown in 
112
Effects of pirfenidone on TGF-β1-stimulated fibroblast activity 113 Pirfenidone inhibited collagen gel contraction of human fetal lung fibroblast-1 (HFL-1) in a 114 concentration-dependent manner, but did not affect chemotaxis when added alone to HFL-1 115 cells (Fig. 1A, C) . 116 Next, we investigated whether pirfenidone altered the TGF-β1-induced increase in 117 collagen gel contraction and chemotaxis towards fibronectin in HFL-1 cells. Pirfenidone 118 treatment reduced TGF-β1-induced collagen gel contraction and chemotaxis in HFL-1 cells in 119 a concentration-dependent manner (P < 0.05 for 100 μg/mL pirfenidone ± 10 pM TGF-β1 120 versus control; Fig. 1A, C) . Pirfenidone abolished HFL-1-mediated gel contraction and 121 chemotaxis in the presence of less than 10 pM TGF-β1 (P < 0.05). However, in the presence 122 of 100 pM TGF-β1, pirfenidone did not inhibit HFL-1-mediated gel contraction and 123 chemotaxis (Fig. 1B, D) . 124 Although the maximum plasma concentration (C max ) of pirfenidone, which is typically 125 used for treating patients with IPF at dosage up to 1800 mg/day, is 15.7 μg/mL after 126 administration of 801 mg pirfenidone (Rubino et al., 2009), higher concentrations may be 127 used; indeed, pirfenidone is widely used at concentrations above 100 μg/mL in vitro in the 128 laboratory setting (Conte et al., 2014). Therefore, we used 100 μg/mL pirfenidone, with or 129 without 10 pM TGF-β1, in our subsequent experiments on adult human primary lung 130
fibroblasts. 131
Notably, gel contraction and chemotaxis were attenuated in cells treated with 100 132 μg/mL pirfenidone alone or in combination with 10 pM TGF-β1 ( Fig. 2A, C) . This inhibitory 133 effect was higher in fibroblasts from fibrotic lungs than in control fibroblasts (gel contraction: 134 P < 0.001 and 0.05, chemotaxis: P < 0.05 and P =0.16, fibrotic vs. normal lung; Fig. 2B, D) . 135 However, there were no differences in the effects of fibrotic lung fibroblasts from patients with 136 UIP compared to those from patients with NSIP. At the end of the incubation, cell numbers or 137 viability in the gels in pirfenidone-and/or TGF-β1-treated groups were not different from those 138 in the control group, as assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assays (data not shown). TGF-β1-induced changes in cytoplasmic CTHRC1 and FHL2 expression levels in fibrotic 145 fibroblasts using immunoblotting. The relative increases in CTHRC1 and FHL2 upon TGF-β1 146 stimulation were higher in fibrotic fibroblasts than in control fibroblasts; however, there were 147 no differences in fibrotic lung fibroblasts between patients with UIP and those with NSIP 148 (CTHRC1: control, P = 0.109 versus lung fibrosis, P = 0.003; FHL2: control, P = 0.360 versus 149 lung fibrosis, P = 0.006; Fig. 3A, B) . Since CTHRC1 is a secreted protein and a previous 150 report showed that CTHRC1 was present in plasma of individual patients (Duarte et al., 151 2014); therefore, we also measured release of CTHRC1 protein from human lung fibroblasts 152 using enzyme-linked immunosorbent assay (ELISA). The relative increases in CTHRC1 153 releasing from fibroblasts upon TGF-β1 stimulation were higher from fibrotic fibroblasts than 154 from control fibroblasts. The fold increase in CTHRC1 in the presence of TGF-β1 stimulation 155 (1.347 ± 0.246 in control fibroblasts versus 3.610 ± 0.662 in fibrotic fibroblasts; P = 0.004) 156 was higher in fibroblasts from fibrotic lungs than in control fibroblasts. The suppressive 157 effects of pirfenidone on CTHRC1 release from TGF-β1-induced fibroblasts was higher in 158 fibrotic lung fibroblasts than in control fibroblasts (control: P = 0.111; IP: P＜0.001); in 159 contrast, the suppressive effects of pirfenidone alone were similar with respect to release of 160 CTHRC1 (control: P = 0.004; IP: P = 0.001). The fold reduction in CTHRC1 in the presence of 161 pirfenidone following TGF-β1 stimulation (0.139 ± 0.069 in control fibroblasts versus 0.400 ±0.064 in fibrotic fibroblasts; P = 0.018) was higher in fibroblasts from fibrotic lungs than in 163 control fibroblasts (All folds calculated by difference value after treatment / initial value ) (Fig. 164 which can modulate chemotaxis and collagen gel contraction in an autocrine or paracrine 168 manner. To determine whether these mediators directly contribute to the suppression of 169 collagen gel contraction and chemotaxis induced by pirfenidone, the release of these 170 mediators into the monolayer culture medium was evaluated using ELISA. Notably, 171 pirfenidone did not affect TGF-β1 levels in culture medium of control and fibrotic fibroblasts 172 (Fig. 3D) . Furthermore, the ability of pirfenidone to modulate PGE 2 release and inducible 173 cyclooxygenase 2 (COX2) expression was further assessed in culture medium from HFL-1 174 cells. Pirfenidone did not stimulate PGE 2 release or COX2 expression with or without TGF-β1 175 in fibroblasts (Fig. S1A, B) . These results indicated that the pirfenidone-regulated molecules 176 CTHRC1 and FHL2 may play a dominant role in pirfenidone-mediated fibroblast activity 177 rather than exert direct effects on TGF-β1-mediated autocrine/paracrine regulation in 178 fibroblasts. 179
180
Effects of pirfenidone on TGF-β1-mediated fibrotic regulators in lung fibroblasts 181 Next, we assessed whether pirfenidone altered targets related to TGF-β1-mediated fibrotic 182 processes in HFL-1 cells. Treatment with pirfenidone significantly reduced 183 TGF-β1-augmented expression of CTHRC1, FHL2, α-SMA, fibronectin, and Gremlin1 184 (P < 0.05; Fig. 4A -E, G) and reversed TGF-β1-dependent suppression of bone morphogenicprotein-4 (BMP4; P < 0.05; Fig. 4A, F) . 186
187
Effects of pirfenidone on CTHRC1-mediated regulation in lung fibroblasts 188 We investigated the effects of recombinant human (rh) CTHRC1 on HFL1-mediated collagen 189 gel contraction and chemotaxis. rhCTHRC1 (10-1000 ng/mL) stimulated gel contraction and 190 chemotaxis toward fibronectin in a concentration-dependent manner (P < 0.05) compared to 191 the control (Fig. 5A-C 
Inhibition of CTHRC1-and FHL2-mediated regulation of HFL-1 201
To investigate the functional roles of the pirfenidone-mediated targets CTHRC1 and FHL2 in 202 lung fibroblasts, we knocked down these targets in HFL-1 cells. Silencing of CTHRC1 led to a 203 complete reversal of targets related to TGF-β1-mediated fibrotic processes, i.e., reduction in 204 FHL2, α-SMA, fibronectin, and Gremlin1 expression and increase in BMP4 expression (Fig. 205 6A). Furthermore, CTHRC1 knockdown attenuated gel contraction and chemotaxis (Fig. 6B,  206 C). However, silencing of FHL2 did not affect CTHRC1, α-SMA , BMP4, and Gremlin1 207 expression and gel contraction, but reduced fibronectin expression and chemotaxis (Fig. 6D,  208 
E). 209 210
Effects of pirfenidone on in vitro TGF-β1-stimulated fibroblast activity and biomarkers 211 of lung fibrosis 212 Considering our observation that pirfenidone in fibrotic lung fibroblasts enhanced their 213 sensitivity to TGF-β1-induced fibrosis compared to normal fibroblasts, we investigated 214 whether our in vitro data was clinically significant. Toward this objective, we measured serum 215 levels of the lung fibrosis biomarkers KL-6 and SP-D in serum of patients with lung fibrosis at In this study, we observed that changes in the fibrotic lung fibroblast phenotype resulted in 227 increased response to the pirfenidone-suppressed bioactivity of lung fibroblasts, leading to 228 inhibition of collagen gel contraction and migration, following TGF-β1-mediated activation. this study, we also demonstrated that FHL2 was further stimulated by TGF-β1 in fibrotic 281 fibroblasts compared to control fibroblasts and that pirfenidone suppressed 282 TGF-β1-stimulated FHL2 expression. However, FHL2 knockdown suppressed only 283 fibronectin expression and migration toward fibronectin, but did not affect gel contraction, 284
other TGF-β1-mediated fibroblast regulators, or CTHRC1 expression. As CTHRC1 285 knockdown attenuated FHL2 expression, FHL2 may play a role in lung fibroblast-mediated 286 fibrosis following TGF-β1-induced upregulation of CTHRC1 (Fig. 7E) . 287 Clinically, patients with IPF who showed predicted vital capacity (VC) of more than 288 70% and lowest oxygen satuation in blood during 6 min walking tests (less than 90% at this study, we demonstrated that the magnitude of pirfenidone-dependent suppression of 295 TGF-β1-induced gel contraction and migration was positively related to serum SP-D levels 296 and negatively related to serum KL-6 levels, but was not related to any other clinical 297
parameters, including histological pattern and lung function (%VC, %FVC, and %DLCO). 298
These diverse phenotypic responses to pirfenidone in fibrotic lung fibroblasts and our in vitro 299 results related to serum biomarkers suggested that the progressive state of lung fibrosis with 300 increasing SP-D/KL-6 ratios may be associated with better clinical outcomes (Fig. 7E) collected from areas of complete fibrosis (resembling a honey comb), avoiding large airways, 339 vessels and pleural surface in the lung fibrosis fibroblast group. These cells were cultured as 340 described above. Cells from the outgrowths of these cells, termed "P0," were frozen for later 341 use; these cells displayed typical fibroblast morphology and were confirmed to be positive for 342 vimentin and negative for cytokeratin. For chemotaxis, three-dimensional collagen gel 343 contraction, and ELISA analyses, primary lung fibroblasts were used at passages 4-6 afterisolation to exclude the effects of differences in passage number and culturing conditions. 345
346

Fibroblast chemotaxis 347
HFL-1 cell chemotaxis was assessed using the Boyden blindwell chamber technique 348 (Neuroprobe, Inc., Gaithersburg, MD, USA) as previously described (Boyden, 1962) . In 349 experiments with TGF-β1 or rhCTHRC1, pirfenidone was added to the wells of the upper 350 chamber, whereas human fibronectin (20 µg/mL) was placed in the bottom chamber as the 351 chemoattractant. The two wells were separated by an 8-µM pore filter (Nucleopore, 352 Pleasanton, CA, USA). The chambers were incubated at 37°C in a humid atmosphere 353 containing 5% CO 2 for 8 h, after which the cells on top of the filter were removed by scraping. 354 The cells that had migrated through the filter were then fixed, stained with DiffQuick Sysmex 355 (16920), and mounted on glass microscope slides. Migration was assessed by counting the 356 number of cells in five high-power fields. Replica experiments were performed in triplicate, 357 and replicates with separate cell cultures were performed on separate occasions. Wells with 358 serum-free DMEM were used as negative controls. 359
360
Collagen gel contraction assay 361
Type I collagen (rat tail tendon collagen) was extracted from rat tail tendons as previously 362 described (Elsdale and Bard, 1972). The effects of pirfenidone on fibroblast-mediated gel 363 contraction were determined in the presence or absence of TGF-β1 or rhCTHRC1 using a 364 modification of the method developed by Bell et al. (Bell et al., 1979) . The floating gels were 365 cultured for up to 3 days, and the ability of the fibroblasts to contact the gels was determined 366 by quantifying the area of the gels daily using an LAS4000 image analyzer (GE HealthcareBio-Science AB, Uppsala, Sweden). Data are expressed as the gel area percentage 368 compared to the original gel size. 369
370
Measurement of CTHRC1, TGF-β1, and PGE 2 levels 371 Cultures were maintained for 48 h to quantify CTHRC1, TGF-β1, and PGE 2 levels. After 48 h, 372 media were collected, frozen, and stored at -80°C until analysis. CTHRC1, TGF-β 1 , and PGE 2 373 production by the cells was determined using human CTHRC1 (LifeSpan BioScienceds, Inc., 374
Seattle, WA, USA), TGF-β 1 (R&D Systems), and PGE 2 immunoassays (Cayman Chemical, 375
Ann Harbor, MI, USA), respectively, according to the manufacturers' instructions. 376 377
Western blot analysis 378
To standardize culture conditions, cells were passaged at a density of 5 × 10 4 cells/mL, 379 cultured for 48 h, and then collected for preparation of whole cell lysates. The medium was 380 changed to DMEM without serum for 24 h, followed by treatment with TGF-β1 (10 pM) or 381 rhCTHRC1 (100 ng/mL) in the presence or absence of pirfenidone (100 μg/mL) for 48 h or 382 with various concentrations of rhCTHRC1 for 8 h. Primary antibodies against the following 383 proteins were used for western blotting: CTHRC1 (1:5000 dilution; Proteintech, Rosemont, IL, 384 USA; cat. no. 16534-1-AP), FHL2 (1:1000 dilution; Abcam, Cambridge, UK; cat. no. ab66399), 385 α-SMA (1:1000 dilution; Sigma-Aldrich; cat. no. A2547), fibronectin (1:1000 dilution; Enzo Life 386 Sciences, Inc., Farmingdale, NY, USA; cat. no. BML-FG6010-0100), BMP-4 (1:1000 dilution; 387
Abcam; cat. no. ab39973), Gremlin1 (1:1000 dilution; Thermo Fisher Scientific, Waltham, MA, 388 USA; cat. no. PA5-13123), β-actin (1:5000 dilution; Wako Pure Chemical Industries; cat. no. 389 visualized using peroxidase-conjugated secondary antibodies and enhanced 391 chemiluminescence with a LAS4000 image analyzer (GE Healthcare Bio-Science AB), and 392 band intensity was analyzed Image Gauge software (LAS-400 Plus; Fujifilm experiments. Student's unpaired t test. *P < 0.05, **P < 0.01, ***P < 0.001. 
